Renal cell carcinoma of end-stage renal disease: A histopathologic and molecular genetic study

被引:0
作者
Hughson, MD
Schmidt, L
Zbar, B
Daugherty, S
Meloni, AM
Silva, FG
Sandberg, AA
机构
[1] NCI, FREDERICK CANC RES & DEV CTR, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21701 USA
[2] NCI, FREDERICK CANC RES & DEV CTR, IMMUNOBIOL LAB, FREDERICK, MD 21701 USA
[3] SW BIOMED RES INST, SCOTTSDALE, AZ USA
[4] UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 1996年 / 7卷 / 11期
关键词
renal cell carcinoma; cancer genetics; ESRD;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Renal cell carcinomas (RCC) are responsible for the deaths of 3% to 4% of patients with ESRD. The clear cell carcinoma of the kidney, which comprises 80% of sporadic RCC within the general population, shows a deletion of gene sequences in the short arm of chromosome 3 (3p) in as many as 100% of cases. The von Hippel-Lindau tumor suppressor gene at 3p25-26 is found to be mutated in the nondeleted allele in 57% of these sporadic clear cell carcinomas. This study was undertaken to determine the histopathologic types of RCC occurring in ESRD patients in the United States and to investigate the frequency with which 3p genetic changes can be found in these ESRD tumors. Seventeen end-stage kidneys containing RCC were collected from 15 ESRD patients at ten US medical centers. The tumors were classified by Thoenes' histopathologic typing. DNA extracted from paraffin blocks of tumor and nontumorous tissue was analyzed by single-stranded conformational polymorphism analysis for von Hippel-Lindau mutations and by microsatellite amplification for deletion of 3p gene sequences. Twenty-one RCC were identified in the 18 kidneys, The 21 RCC were classified histopathologically as follows: clear cell, compact, three cases; chromophilic, tubulopapillary, 15 cases; chromophilic, compact, three cases. Among the three clear cell carcinomas, one showed 3p genetic loss, None of the chromophilic RCC showed a 3p deletion and none of 19 tumors studied by single-stranded conformational polymorphism analysis disclosed von Hippel-Lindau mutations. In contrast to the general population, clear cell RCC with 3p abnormalities represent only a small proportion of the renal carcinomas in this collection of ESRD tumors. The findings indicate that the genetic changes underlying the development of most ESRD tumors are different from those occurring in sporadic clear cell RCC and do not characteristically involve the inactivation of a 3p tumor suppressor gene.
引用
收藏
页码:2461 / 2468
页数:8
相关论文
共 50 条
  • [31] Renal replacement modality and stroke risk in end-stage renal disease-a national registry study
    Findlay, Mark
    MacIsaac, Rachael
    MacLeod, Mary Joan
    Metcalfe, Wendy
    Traynor, Amie P.
    Dawson, Jesse
    Mark, Patrick B.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (09) : 1564 - 1571
  • [32] Vitamin D receptor genetic variants among patients with end-stage renal disease
    Tripathi, Gaurav
    Sharma, Richa
    Sharma, Raj K.
    Gupta, Sushil Kumar
    Sankhwar, Satya Narayan
    Agrawal, Suraksha
    RENAL FAILURE, 2010, 32 (08) : 969 - 977
  • [33] Serum albumin concentration and risk of end-stage renal disease: the REGARDS study
    Walther, Carl P.
    Gutierrez, Orlando M.
    Cushman, Mary
    Judd, Suzanne E.
    Lang, Joshua
    McClellan, William
    Muntner, Paul
    Sarnak, Mark J.
    Shlipak, Michael G.
    Warnock, David G.
    Katz, Ronit
    Ix, Joachim H.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (10) : 1770 - 1777
  • [34] Clear Cell-Papillary Renal Cell Carcinoma of the Kidney Not Associated With End-stage Renal Disease Clinicopathologic Correlation With Expanded Immunophenotypic and Molecular Characterization of a Large Cohort With Emphasis on Relationship With Renal Angiomyoadenomatous Tumor
    Aron, Manju
    Chang, Elena
    Herrera, Loren
    Hes, Ondrej
    Hirsch, Michelle S.
    Comperat, Eva
    Camparo, Philippe
    Rao, Priya
    Picken, Maria
    Michal, Michal
    Montironi, Rodolfo
    Tamboli, Pheroze
    Monzon, Federico
    Amin, Mahul B.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (07) : 873 - 888
  • [35] The assessment of coronary artery disease in patients with end-stage renal disease
    Poli, Federica E.
    Gulsin, Gaurav S.
    McCann, Gerry P.
    Burton, James O.
    Graham-Brown, Matthew P.
    CLINICAL KIDNEY JOURNAL, 2019, 12 (05) : 721 - 734
  • [36] Vascular calcification in a young patient with end-stage renal disease
    Chan, Winnie K. Y.
    Lee, K. W.
    But, W. M.
    Chau, K. F.
    HONG KONG MEDICAL JOURNAL, 2013, 19 (02) : 178 - 181
  • [37] Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease
    Foley, RN
    Parfrey, PS
    Harnett, JD
    Kent, GM
    Murray, DC
    Barre, PE
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (05): : 728 - 736
  • [38] Managing End-Stage Renal Disease: An Alphabetized Mnemonic Strategy
    El Hussein, Mohamed Toufic
    Kilfoil, Lauren
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2019, 15 (10): : 732 - 736
  • [39] End-stage renal disease secondary to renal malignancy: Epidemiologic trends and survival outcomes
    Nguyen, Kevin A.
    Vourganti, Srinivas
    Syed, Jamil S.
    Luciano, Randy
    Campbell, Steven C.
    Shuch, Brian
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (08) : 529.e1 - 529.e7
  • [40] Global challenges posed by the growth of end-stage renal disease
    Wetmore J.B.
    Collins A.J.
    Renal Replacement Therapy, 2 (1)